Login / Signup

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.

Giovanni FucàRomain CohenSara LonardiKohei ShitaraMaria Elena ElezMarwan FakihJoseph ChaoSamuel J KlempnerMatthew EmmettPriya JayachandranFrancesca BergamoMarc Díez GarcíaGiacomo MazzoliLeonardo ProvenzanoRaphael ColleMagali SvrcekMargherita AmbrosiniGiovanni RandonAakash Tushar ShahMassimiliano SalatiElisabetta FenocchioLisa SalvatoreKeigo ChidaAkihito KawazoeVeronica ConcaGiuseppe CuriglianoFrancesca CortiChiara CremoliniMichael OvermanThierry AndréFilippo Pietrantonio
Published in: Journal for immunotherapy of cancer (2022)
Patients with dMMR/MSI-H gastrointestinal cancers with peritoneal metastases and ascites should be considered as a peculiar subgroup with highly unfavorable outcomes to current ICI-based therapies. Novel strategies to target the immune-suppressive niche in malignant effusions should be investigated, as well as next-generation ICIs or intraperitoneal approaches.
Keyphrases
  • cell free
  • squamous cell carcinoma
  • small cell lung cancer
  • atomic force microscopy
  • type diabetes
  • randomized controlled trial
  • metabolic syndrome
  • skeletal muscle
  • insulin resistance
  • study protocol
  • single molecule